share_log

6,894 Shares in ZimVie Inc. (NASDAQ:ZIMV) Purchased by Oregon Public Employees Retirement Fund

6,894 Shares in ZimVie Inc. (NASDAQ:ZIMV) Purchased by Oregon Public Employees Retirement Fund

俄勒岡州公共僱員退休基金購買的 6,894 股 ZIMVIE 公司(納斯達克:ZIMV)
Defense World ·  2023/01/29 06:32

Oregon Public Employees Retirement Fund bought a new stake in ZimVie Inc. (NASDAQ:ZIMV – Get Rating) in the third quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund bought 6,894 shares of the company's stock, valued at approximately $68,000.

根據俄勒岡州公共僱員退休基金最近向證券交易委員會提交的文件,俄勒岡州公共僱員退休基金在第三季度收購了 ZimVie Inc.(NASDAQ:ZIMV-獲得評級)的新股份。基金買入該公司股票的 6,894 股,價值約 68,000 美元。

Other hedge funds and other institutional investors also recently bought and sold shares of the company. Monarch Capital Management Inc. acquired a new position in ZimVie in the third quarter valued at approximately $227,000. Hellman Jordan Management Co. Inc. MA acquired a new position in ZimVie in the second quarter valued at approximately $724,000. Douglas Lane & Associates LLC acquired a new position in ZimVie in the third quarter valued at approximately $192,000. Raymond James & Associates acquired a new position in ZimVie in the third quarter valued at approximately $110,000. Finally, Comerica Bank acquired a new position in ZimVie in the third quarter valued at approximately $110,000. 74.29% of the stock is currently owned by institutional investors and hedge funds.

其他對沖基金和其他機構投資者最近也買賣了該公司的股票。君主資本管理公司在第三季度收購了 ZimVie 的新職位,價值約為 227,000 美元。赫爾曼佐敦管理公司MA 公司在第二季度收購了 ZimVie 的新職位,價值約為 724,000 美元。道格拉斯巷 & 聯營有限責任公司在第三季度收購了 ZimVie 的新位置,價值約為 $192,000.雷蒙德詹姆斯 & 同事在第三季度收購了 ZimVie 的新職位,價值約為 $110,000.最後,美信銀行在第三季度收購了 ZimVie 的新倉位,價值約為 11 萬美元。74.29% 的股票目前由機構投資者和對沖基金擁有。

Get
取得
ZimVie
ZimVie
alerts:
警報:

Analyst Upgrades and Downgrades

分析師升級和降級

Separately, Barclays assumed coverage on ZimVie in a research note on Wednesday, December 21st. They issued an "underweight" rating and a $9.00 target price for the company.

另外,巴克萊在 12 月 21 日星期三的研究筆記中承擔了 ZimVie 的報導。他們為該公司發布了「體重不足」評級和 9.00 美元的目標價格。

ZimVie Price Performance

價格表現

Shares of NASDAQ ZIMV opened at $9.09 on Friday. The company has a current ratio of 2.51, a quick ratio of 1.48 and a debt-to-equity ratio of 0.76. The stock has a 50 day simple moving average of $8.95 and a 200-day simple moving average of $11.74. ZimVie Inc. has a 12-month low of $6.67 and a 12-month high of $50.40.
納斯達克 ZIMV 的股票上週五開盤 9.09 美元。該公司的流動比率為 2.51,快速比率為 1.48,債務與權益比率為 0.76。該股票有 50 天的簡單移動平均線為 8.95 美元,以及 200 天的簡單移動平均線為 11.74 美元。Zimvie 公司擁有 12 個月低點 6.67 美元和 12 個月高點為 50.40 美元。

ZimVie (NASDAQ:ZIMV – Get Rating) last issued its quarterly earnings data on Wednesday, November 9th. The company reported $0.49 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.27 by $0.22. The business had revenue of $214.58 million during the quarter, compared to the consensus estimate of $214.83 million. ZimVie had a negative return on equity of 2.75% and a negative net margin of 9.96%. On average, equities analysts expect that ZimVie Inc. will post 1.95 earnings per share for the current year.

ZimVie (納斯達克:ZIMV — 獲得評分) 上週三公佈了其季度收益數據,週三, 11 月 9 日.該公司報告了該季度的每股盈利 0.49 美元,超過 0.27 美元的一致預估值 0.22 美元。該業務在本季度的收入為 214.58 億美元,而共識估計為 214.83 億美元。ZimVie 的資產回報率為 2.75%,負淨利潤率為 9.96%。平均而言,股票分析師預計,ZimVie Inc. 將在本年度公佈每股盈利 1.95。

About ZimVie

關於濟威

(Get Rating)

(取得評分)

ZimVie Inc, a medical technology company, develops, manufactures, and delivers a portfolio of products and solutions designed to treat a range of spine pathologies, and support dental tooth replacement and restoration procedures worldwide. It offers dental implant systems, prosthetic and abutment products, surgical instrumentation, and kits; bone grafts, barrier membranes, allografts, and collagen wound care products; intraoral scanners; and virtual treatment planning services, guided surgery solutions, CAD/CAM workflow systems, and patient-specific restorative components and intra-oral scanners, as well as spinal fusion implants and instrumentation for various spinal procedures, biologics, and bone healing technologies.

ZimVie Inc 是一家醫療技術公司,致力於開發、製造和提供一系列產品和解決方案,旨在治療一系列脊柱病變,並在全球範圍內支持牙齒置換和修復程序。它提供牙科植入系統,假肢和基台產品,手術儀器和套件; 骨移植,屏障膜,異體移植物和膠原蛋白傷口護理產品; 口腔掃描儀; 和虛擬治療規劃服務,指導手術解決方案,CAD/CAM 工作流系統,以及患者特定的修復組件和口腔內掃描儀,以及脊柱融合植入物和脊柱植入物和治療儀器,各種脊柱植入物和治療技術。

Recommended Stories

推薦故事

  • Get a free copy of the StockNews.com research report on ZimVie (ZIMV)
  • MarketBeat Week in Review – 1/23- 1/27
  • Why Lucid Spiked Nearly 100% In One Day
  • Ride These Railroad Stocks for Growth and Income
  • ASML Sees Demand For Chips Rallying This Year, Boosts Sales View
  • KLA Corporation: Strength In A Troubled Semi-Market
  • 免費獲取有關 ZIMVIE(ZIMV)的研究報告
  • 市場節拍週的回顧 — 1/23-1/27
  • 為什麼清醒在一天內飆升近 100%
  • 乘坐這些鐵路股票以獲得增長和收入
  • ASML 今年看到籌碼需求上升,提高了銷售觀點
  • KLA 公司:陷入困境的半市場中的實力

Want to see what other hedge funds are holding ZIMV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for ZimVie Inc. (NASDAQ:ZIMV – Get Rating).

想看看還有哪些對沖基金持有 ZIMV? 訪問控股公司獲取有關 ZimVie 公司(納斯達克:ZIMV-獲取評級)的最新 13 樓文件和內幕交易。

Receive News & Ratings for ZimVie Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ZimVie and related companies with MarketBeat.com's FREE daily email newsletter.

接收 ZimVie 日報的最新消息和評分 -在下面輸入您的電子郵件地址,以通過 MarketBeat.com 的免費每日電子郵件通訊接收 ZimVie 及相關公司的最新新聞和分析師評級的簡要每日摘要。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論